Tecentriq (atezolizumab) gets Infarmed approval for new indications
The drug Tecentriq (atezolizumab) obtained authorization from the National Authority for Medicines and Health Products (Infarmed) to be used in hospitals in new indications for the treatment of lung cancer.
According to the grant recently published on the Infarmed website, Tecentriq (atezolizumab), in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with large-scale small cell lung cancer (SCLC-ED). It is important to mention that this is the first therapeutic innovation in more than 20 years for these patients.
Additionally and according to this publicly released note, Tecentriq (Atezolizumab) monotherapy is indicated for the first-line treatment of adult patients with metastatic Non-Small Cell Lung Cancer (NSCLC) whose tumors have a PD-L1 expression of ≥ 50 % of tumor cells (CT) or ≥ 10% of tumor-infiltrating immune cells (CI) that do not have EGFR-mutated or ALK-positive mNSCC.
At the same time, the 840mg ampoule was also financed, which now allows for greater dosage flexibility with Atezolizumab. Tecentriq (Atezolizumab), in combination or monotherapy, can be administered: 1) every 4 weeks – 1680 mg (2 ampoules of 840 mg); 2) every 3 weeks – 1200 mg ampoule; 3) every 2 weeks – 840 mg ampoule.
Good news for the national panorama in the provision of treatments for patients with lung cancer.
Learn more about public reports on the Infarmed website by searching for “Atezolizumab” on the drug page.